Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

GlaxoSmithKline

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced a mutual decision with GSK to terminate their agreement on bintrafusp alfa, effective September 30, 2021. The decision is based on the clinical trial data generated to date, most notably the previously reported results from the INTR@PID Lung 037 study, which did not replicate the encouraging data observed in earlier studies. Based on the data generated during the agreement, no milestone payment

Merck Announces Mutual Decision to End Bintrafusp Alfa Agreement With GSK

Acceleron Pharma

Merck will spend about $11.5 billion to buy Acceleron Pharma and its potential treatment for high blood pressure in vessels that connect the lungs heart.

Merck buying Acceleron Pharma in $11.5B deal

Sutro Biopharma Inc

Merck & Co Inc (NYSE: MRK) has extended the research term by two years for the first cytokine derivative program under a 2018 agreement with Sutro Biopharma Inc (NASDAQ: STRO). The research extension is intended to facilitate preclinical research and development activities for a second candidate with a novel design and approach.

Merck, Sutro Biopharma Extends Cytokine Derivative Research Program

The move will boost Merck's current pipeline with Acceleron's drugs that treat rare diseases.

Merck and Acceleron Pharma Agree a $11.5 Billion Deal. The Shares Are Up.

Putting all the speculations at bay, Merck & Co Inc (NYSE: MRK) has agreed to acquire Acceleron Pharma Inc (NASDAQ: XLRN) for $180 per share in cash for an approximate total equity value of $11.5 billion. Related Link:   Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ.

Merck Seals Acceleron Pharma Deal For $180/Share: Highlights

Merck & Co will buy drugmaker Acceleron Pharma Inc for about $11.5 billion, the companies said on Thursday, as the U.S. pharmaceutical giant looks to beef up its portfolio with drugs for rare diseases.

Merck to buy Acceleron for about $11.5 billion in rare disease drugs push

Merck & Co. MRK, +2.41% said Thursday it has agreed to acquire Acceleron Pharma Inc. XLRN, -4.06% in a deal with an equity value of $11.5 billion that was first reported earlier this week by the Wall Street Journal. Merck will pay $180 in cash for each Acceleron share owned, in a deal that's expected to close in the fourth quarter.

Merck confirms to acquire Acceleron in a deal valued at $11.5 billion

KENILWORTH, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Acquire Acceleron Pharma Inc.

Merck to Acquire Acceleron Pharma Inc.

Merck & Co Inc (NYSE: MRK) presented a study at a medical conference early Wednesday for its experimental COVID-19 antiviral candidate. What Happened: Laboratory studies' data showed that molnupiravir is active against variants of the virus.

Merck's COVID-19 Antiviral Pill Effective Against Variants, Lab Studies Show

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Appointment of Thomas H. Glocer as Independent Lead Director

Merck Announces Appointment of Thomas H. Glocer as Independent Lead Director

AbbVie

Horizon Pharma

Johnson & Johnson

Eli Lilly

Novartis

Regeneron Pharmaceuticals

These biotech stocks offer a more mature take on an otherwise risky sector. These companies already have successes under their belt.

7 Biotech Stocks Entering the Golden Boom Phase

Merck's (MRK) Keytruda achieves both primary and secondary endpoints in a phase III study evaluating the drug in patients with advanced hepatocellular carcinoma.

Merck (MRK) Keytruda Meets Hepatocellular Carcinoma Study Goal

Chevron

Dow Inc

Coca-Cola

It seems hard to believe, but the third quarter is almost over and only one quarter remains in 2021.

5 Dow Stocks With the Biggest Dividends Are Great Q4 Buys Now

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Third-Quarter 2021 Sales and Earnings Conference Call on October 28

Merck to Hold Third-Quarter 2021 Sales and Earnings Conference Call on October 28

Acceleron produces a drug to treat pulmonary arterial hypertension and Reblozyl, used against blood-related disorders.

Merck Reportedly Close to Buying Acceleron Pharma

The Wall Street Journal reported that Merck & Co Inc (NYSE: MRK) is in advanced talks to acquire Acceleron Pharma Inc (NASDAQ: XLRN), citing people familiar with the matter. The deal for Acceleron, which has a market value of around $11 billion, could be announced this week, assuming talks don't fall apart, the people said.

Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ

Merck is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant's rare-disease business.

The Wall Street Journal: Merck nears deal for rare-disease-drug maker Acceleron

Merck & Co. is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant's rare-disease business.

Merck nears deal to acquire Acceleron Pharma

Merck (MRK) closed the most recent trading day at $73.36, moving -0.34% from the previous trading session.

Merck (MRK) Dips More Than Broader Markets: What You Should Know

Merck & Co is in advanced talks to acquire drugmaker Acceleron Pharma Inc, the Wall Street Journal reported https://www.wsj.com/articles/merck-nears-deal-to-acquire-acceleron-pharma-11632778405?mod=latest_headlines on Monday, citing people familiar with the matter.

Merck in advanced talks to buy Acceleron Pharma

AstraZeneca

AstraZeneca (AZN) and Merck (MRK) announce that their PARP inhibitor Lynparza succeeds in meeting the primary endpoint in a late-stage study, evaluating it in first-line castration-resistant prostate cancer patients.

AstraZeneca, Merck's Lynparza Prostate Cancer Study Meets Goal

Merck & Co Inc (NYSE: MRK) has announced topline data from Phase 3 KEYNOTE-394 trial of Keytruda in Asian patients with advanced hepatocellular carcinoma (HCC). The trial included HCC patients previously treated with sorafenib.

Merck's Keytruda Tops Placebo On Overall Survival Endpoint In Liver Cancer Patients

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #merck--Merck Announces KEYTRUDA® Met Primary Endpoint of Overall Survival in Patients w/Advanced Hepatocellular Carcinoma Previously Treated w/Sorafenib.

Merck Announces KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib

AstraZeneca Plc (NASDAQ: AZN) has reported high-level results from the PROpel Phase 3 trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC). The data showed Lynparza plus abiraterone demonstrated improvement in radiographic progression-free survival (rPFS) versus abiraterone as a 1st-line treatment for mCRPC with or without homologous recombination repair (HRR) gene mutations.

AstraZeneca - Merck's Lynparza Delays Disease Progression In Prostate Cancer Patients

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial

LYNPARZA® (olaparib) in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC)

News for Merck Stock (MRK)